Infiltrating urothelial carcinoma
MONDO:0040678A invasive carcinoma that involves the urothelium.
Also known as: infiltrating transitional cell carcinoma of the urinary tract, infiltrating urothelial carcinoma
2941 clinical trials for this condition and its sub-types, 5 tagged with Infiltrating urothelial carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Infiltrating urothelial carcinoma
-
Infiltrating bladder urothelial carcinoma 181 trials · 183 incl. sub-types
9 sub-types
- Infiltrating bladder urothelial carcinoma sarcomatoid variant 5 trials
- Plasmacytoid variant infiltrating bladder urothelial carcinoma 4 trials
- Micropapillary variant infiltrating bladder urothelial carcinoma 3 trials
- Infiltrating bladder lymphoepithelioma-like carcinoma 1 trial
- Nested variant infiltrating bladder urothelial carcinoma 1 trial
- Infiltrating bladder urothelial carcinoma, clear cell variant 0 trials
- Lipid-cell variant infiltrating bladder urothelial carcinoma 0 trials
- Lymphoma-like variant infiltrating bladder urothelial carcinoma 0 trials
- Microcystic variant infiltrating bladder urothelial carcinoma 0 trials
-
2 sub-types
-
Blood test may tell who needs extra immunotherapy after bladder cancer surgery
Disease control Recruiting nowThis large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to outsmart resistant bladder cancer
Disease control Recruiting nowThis phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC